<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00123305</url>
  </required_header>
  <id_info>
    <org_study_id>TG-M-004</org_study_id>
    <nct_id>NCT00123305</nct_id>
  </id_info>
  <brief_title>Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke</brief_title>
  <official_title>A Multicentre, Double-Blind, Placebo-Controlled, Ascending-dose, Clinical Trial of Intravenous Microplasmin Administration in Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ThromboGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ThromboGenics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety and preliminary efficacy of
      microplasmin when administered intravenously to patients who have suffered an acute stroke
      within 12 hours before randomization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While the primary objective of the trial is safety evaluation, efficacy assessments will also
      be obtained, including MRI/MRA (including DWI, PWI and T2 imaging) and plasma surrogate
      biomarkers. Clinical outcome will also be assessed at 7days, 30 days and 90 days
      post-treatment. At each of these visits, mortality and neurological assessments (NIHSS,
      Barthel index, mRankin scale) will be performed. In addition, vital status will be assessed
      vial a telephone contact at 60 days post-treatment.

      The trial will investigate three dose regimens of microplasmin, all of which are within the
      range of doses previously evaluated in a Phase I trial in healthy volunteers; the planned
      sample size for the trial is approximately 40 patients.

      The study will consist of 3 phases - the Baseline, In-hospital Phase and Follow up Phase.
      Baseline is from study entry through randomisation; the In-hospital phase is from treatment
      with study drug through hospital discharge or day 7, whichever occurs first. The follow up
      phase consists of visits to the hospital 30 days (+ 3 days) from the day of study drug
      administration. Hospital discharge is defined as the end of the discharge from the acute
      hospital setting. Discharge may be to home, to a rehabilitation setting or to a non-acute
      hospital setting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial haemorrhage</measure>
    <time_frame>24 hours and Day-7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in NIHSS</measure>
    <time_frame>Day7 and Day-90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barthel Index and modified Rankin scale</measure>
    <time_frame>Day-90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of systemic lysis</measure>
    <time_frame>Baseline, end of treatment, 6, 12, 24, 72 and 96 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microplasmin</intervention_name>
    <description>1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microplasmin</intervention_name>
    <description>1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute ischemic stroke with onset within 12 hours before randomization with baseline
             NIHSS &gt; 6 and &lt; 22

        Exclusion Criteria:

        General Exclusion Criteria

          -  Participation in another study with an investigational drug or device within the
             previous 30 days, prior participation in the present study, or planned participation
             in another trial within the time frame of the current trial

          -  Symptoms suggestive of subarachnoid hemorrhage, even if CT scan or MRI is negative for
             hemorrhage

          -  Women known to be pregnant, lactating, or having a positive or indeterminate pregnancy
             test

        Stroke Related Exclusion Criteria

          -  Neurological deficit that has led to stupor or coma (National Institutes of Health
             Stroke Scale [NIHSS] Level Of Consciousness Item 1a score &gt;or=2)

          -  High clinical suspicion of septic embolus

          -  Thrombosis involving cerebral veins

          -  Rapidly improving neurological signs at any time before initiation of study drug
             administration

        Imaging Related Exclusion Criteria

          -  Hemorrhagic transformation or intracerebral hemorrhage observed on baseline CT of the
             brain or gradient recalled echo (GRE) magnetic resonance imaging

          -  CT or MRI evidence of nonvascular cause for the neurological symptoms

          -  Large hypodensity on CT involving &gt; 1/3 of the middle cerebral artery (MCA) territory

          -  Baseline DWI volume &gt; 1/3 of the MCA territory

          -  Signs of mass effect causing shift of midline structures on CT or MRI

          -  Unable to undergo MRI (i.e., ferrous implants, cardiac pacemakers, agitation,
             claustrophobia or known sensitivity to MRI contrast agents)

        Safety Related Exclusion Criteria

          -  Congenital or acquired coagulopathy causing either of the following

               1. activated partial thromboplastin time prolongation greater than 2 seconds above
                  the upper limit of normal (ULN) for local laboratory

               2. International normalized ratio (INR) of 1.4 or more.

          -  Uncontrolled hypertension defined as a systolic blood pressure &gt; 180 mm Hg or a
             diastolic blood pressure &gt; 100 mm Hg on 3 separate occasions at least 10 minutes apart
             or requiring continuous intravenous (IV) therapy.

          -  History of stroke within the previous 3 months

          -  Seizures at any time between stroke onset to planned initiation of study drug

          -  History of intracranial hemorrhage

          -  History of surgery, lumbar puncture, biopsy or trauma to internal organs within the
             previous 30 days.

          -  Major trauma at the time of stroke

          -  Head trauma within the previous 90 days.

          -  Known bleeding diathesis.

          -  Baseline platelet count &lt; 100 X 10^9/L.

          -  Blood glucose &gt; 400mg/dl or &lt;50 mg/dl if administration of glucose does not rapidly
             reverse neurological deficit

        Exclusion Criteria That May Potentially Interfere with Outcome Assessment

          -  Life expectancy &lt;3 months

          -  Other serious illness that in the opinion of the investigator may confound clinical
             assessment (e.g. hepatic, cardiac, or renal failure, advanced cancer)

        Exclusion Criteria Related to Concomitant Medication

          -  If treatment with tPA is indicated

          -  Treatment with rtPA or any other thrombolytic agent for the qualifying stroke

          -  Administration of intra-arterial or systemic thrombolytic therapy in previous 7 days

          -  Need for antiplatelet agent, unfractionated or heparin-related products, direct
             thrombin inhibitor, oral anticoagulant within 24 hours after treatment bolus.

          -  Treatment with low molecular weight heparin, direct thrombin inhibitor, or GPIIb/IIIa
             antagonists within 48 hours prior to randomisation

          -  Treatment with vitamin-K antagonists or heparin (or heparin-related compounds) which
             results in either an INR&gt;1.4 or an aPTT&gt;2 times control (ULN for the hospital
             laboratory)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Thijs, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KU Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitatsklinik fur Neurologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landesnervenklinik Wagner-Jauregg</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Linz Neurolog Abt</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Offentliches Krankenhaus der</name>
      <address>
        <city>Linz</city>
        <zip>A-4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gasthuisburg Hospital</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W Goethe Univeristy</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georg August Universitat Gottingen</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatskrankenhaus Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Minden, Chefarzt der Neurologischen Klinik</name>
      <address>
        <city>Minden</city>
        <zip>32427</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HSK Dr. Horst Schmidt Hospital</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2005</study_first_submitted>
  <study_first_submitted_qc>July 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2005</study_first_posted>
  <last_update_submitted>November 6, 2014</last_update_submitted>
  <last_update_submitted_qc>November 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Acute Ischemic Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Fibrinolysin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

